Summary

Peptide Therapeutics Contract API Manufacturing Market – Scope of Report
TMR’s report on the global peptide therapeutics contract API manufacturing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global peptide therapeutics contract API manufacturing market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide therapeutics contract API manufacturing market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the peptide therapeutics contract API manufacturing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peptide therapeutics contract API manufacturing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peptide therapeutics contract API manufacturing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peptide therapeutics contract API manufacturing market.

The report delves into the competitive landscape of the global peptide therapeutics contract API manufacturing market. Key players operating in the global peptide therapeutics contract API manufacturing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peptide therapeutics contract API manufacturing market profiled in this report.

Key Questions Answered in Global peptide therapeutics contract API manufacturing Market Report
• What is the sales/revenue generated by peptide therapeutics contract API manufacturing across all regions during the forecast period?
• What are the opportunities in the global peptide therapeutics contract API manufacturing market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Peptide Therapeutics Contract API Manufacturing Market – Research Objectives and Research Approach
The comprehensive report on the global peptide therapeutics contract API manufacturing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peptide therapeutics contract API manufacturing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peptide therapeutics contract API manufacturing market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Peptide Therapeutics Contract API Manufacturing Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product /Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast, by Scale of Operation
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Scale of Operation, 2020-2034
        6.3.1. Preclinical/Clinical
        6.3.2. Commercial
    6.4. Market Attractiveness Analysis, by Scale of Operation
7. Global Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast, by Type of Synthesis Method Used
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
        7.3.1. Non-chemical Synthesis Method
        7.3.2. Chemical Synthesis Method
    7.4. Market Attractiveness Analysis, by Type of Synthesis Method Used
8. Global Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast, by Enterprise Type
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Enterprise Type, 2020-2034
        8.3.1. Large Enterprise
        8.3.2. Small and Medium Enterprise
    8.4. Market Attractiveness Analysis, by Enterprise Type
9. Global Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2020-2034
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Scale of Operation, 2020-2034
        10.3.1. Preclinical/Clinical
        10.3.2. Commercial
    10.4. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
        10.4.1. Non-chemical Synthesis Method
        10.4.2. Chemical Synthesis Method
    10.5. Market Value Forecast, by Enterprise Type, 2020-2034
        10.5.1. Large Enterprise
        10.5.2. Small and Medium Enterprise
    10.6. Market Value Forecast, by Country, 2020-2034
        10.6.1. U.S.
        10.6.2. Canada
    10.7. Market Attractiveness Analysis
        10.7.1. By Scale of Operation
        10.7.2. By Type of Synthesis Method Used
        10.7.3. By Enterprise Type
        10.7.4. By Country
11. Europe Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Scale of Operation, 2020-2034
        11.3.1. Preclinical/Clinical
        11.3.2. Commercial
    11.4. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
        11.4.1. Non-chemical Synthesis Method
        11.4.2. Chemical Synthesis Method
    11.5. Market Value Forecast, by Enterprise Type, 2020-2034
        11.5.1. Large Enterprise
        11.5.2. Small and Medium Enterprise
    11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        11.6.1. Germany
        11.6.2. U.K.
        11.6.3. France
        11.6.4. Italy
        11.6.5. Spain
        11.6.6. Rest of Europe
    11.7. Market Attractiveness Analysis
        11.7.1. By Scale of Operation
        11.7.2. By Type of Synthesis Method Used
        11.7.3. By Enterprise Type
        11.7.4. By Country/Sub-region
12. Asia Pacific Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Scale of Operation, 2020-2034
        12.3.1. Preclinical/Clinical
        12.3.2. Commercial
    12.4. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
        12.4.1. Non-chemical Synthesis Method
        12.4.2. Chemical Synthesis Method
    12.5. Market Value Forecast, by Enterprise Type, 2020-2034
        12.5.1. Large Enterprise
        12.5.2. Small and Medium Enterprise
    12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.6.1. China
        12.6.2. Japan
        12.6.3. India
        12.6.4. Australia & New Zealand
        12.6.5. Rest of Asia Pacific
    12.7. Market Attractiveness Analysis
        12.7.1. By Scale of Operation
        12.7.2. By Type of Synthesis Method Used
        12.7.3. By Enterprise Type
        12.7.4. By Country/Sub-region
13. Latin America Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Scale of Operation, 2020-2034
        13.3.1. Preclinical/Clinical
        13.3.2. Commercial
    13.4. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
        13.4.1. Non-chemical Synthesis Method
        13.4.2. Chemical Synthesis Method
    13.5. Market Value Forecast, by Enterprise Type, 2020-2034
        13.5.1. Large Enterprise
        13.5.2. Small and Medium Enterprise
    13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.6.1. Brazil
        13.6.2. Mexico
        13.6.3. Rest of Latin America
    13.7. Market Attractiveness Analysis
        13.7.1. By Scale of Operation
        13.7.2. By Type of Synthesis Method Used
        13.7.3. By Enterprise Type
        13.7.4. By Country/Sub-region
14. Middle East & Africa Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast
    14.1. Introduction
    14.2. Key Findings
    14.3. Market Value Forecast, by Scale of Operation, 2020-2034
        14.3.1. Preclinical/Clinical
        14.3.2. Commercial
    14.4. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
        14.4.1. Non-chemical Synthesis Method
        14.4.2. Chemical Synthesis Method
    14.5. Market Value Forecast, by Enterprise Type, 2020-2034
        14.5.1. Large Enterprise
        14.5.2. Small and Medium Enterprise
    14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        14.6.1. GCC Countries
        14.6.2. South Africa
        14.6.3. Rest of Middle East & Africa
    14.7. Market Attractiveness Analysis
        14.7.1. By Scale of Operation
        14.7.2. By Type of Synthesis Method Used
        14.7.3. By Enterprise Type
        14.7.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2023)
    15.3. Company Profiles
        15.3.1. Ambiopharm Inc
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Financial Overview
            15.3.1.5. Strategic Overview
        15.3.2. Auspep
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Financial Overview
            15.3.2.5. Strategic Overview
        15.3.3. Bachem Holding AG
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Financial Overview
            15.3.3.5. Strategic Overview
        15.3.4. BCN Peptides
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Financial Overview
            15.3.4.5. Strategic Overview
        15.3.5. Chinese Peptide Company
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Financial Overview
            15.3.5.5. Strategic Overview
        15.3.6. CordenPharma
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Financial Overview
            15.3.6.5. Strategic Overview
        15.3.7. CPC Scientific
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Financial Overview
            15.3.7.5. Strategic Overview
        15.3.8. Creative Peptides
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Financial Overview
            15.3.8.5. Strategic Overview
        15.3.9. CSBio
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Financial Overview
            15.3.9.5. Strategic Overview
        15.3.10. Hybio Pharmaceutical
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Financial Overview
            15.3.10.5. Strategic Overview
        15.3.11. Peptide Institute, Inc.
            15.3.11.1. Company Overview
            15.3.11.2. Product Portfolio
            15.3.11.3. SWOT Analysis
            15.3.11.4. Financial Overview
            15.3.11.5. Strategic Overview
        15.3.12. PolyPeptide Group
            15.3.12.1. Company Overview
            15.3.12.2. Product Portfolio
            15.3.12.3. SWOT Analysis
            15.3.12.4. Financial Overview
            15.3.12.5. Strategic Overview
        15.3.13. ScinoPharm
            15.3.13.1. Company Overview
            15.3.13.2. Product Portfolio
            15.3.13.3. SWOT Analysis
            15.3.13.4. Financial Overview
            15.3.13.5. Strategic Overview
        15.3.14. Senn Chemicals AG
            15.3.14.1. Company Overview
            15.3.14.2. Product Portfolio
            15.3.14.3. SWOT Analysis
            15.3.14.4. Financial Overview
            15.3.14.5. Strategic Overview